Cargando…

PPAR Beta/Delta and the Hallmarks of Cancer

Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. Three different isoforms, PPAR alpha, PPAR beta/delta and PPAR gamma have been identified. They all form heterodimers with retinoic X receptors to activate or repress downstream target genes dependent...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Nicole, Wagner, Kay-Dietrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291220/
https://www.ncbi.nlm.nih.gov/pubmed/32375405
http://dx.doi.org/10.3390/cells9051133
_version_ 1783545859538944000
author Wagner, Nicole
Wagner, Kay-Dietrich
author_facet Wagner, Nicole
Wagner, Kay-Dietrich
author_sort Wagner, Nicole
collection PubMed
description Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. Three different isoforms, PPAR alpha, PPAR beta/delta and PPAR gamma have been identified. They all form heterodimers with retinoic X receptors to activate or repress downstream target genes dependent on the presence/absence of ligands and coactivators or corepressors. PPARs differ in their tissue expression profile, ligands and specific agonists and antagonists. PPARs attract attention as potential therapeutic targets for a variety of diseases. PPAR alpha and gamma agonists are in clinical use for the treatment of dyslipidemias and diabetes. For both receptors, several clinical trials as potential therapeutic targets for cancer are ongoing. In contrast, PPAR beta/delta has been suggested as a therapeutic target for metabolic syndrome. However, potential risks in the settings of cancer are less clear. A variety of studies have investigated PPAR beta/delta expression or activation/inhibition in different cancer cell models in vitro, but the relevance for cancer growth in vivo is less well documented and controversial. In this review, we summarize critically the knowledge of PPAR beta/delta functions for the different hallmarks of cancer biological capabilities, which interplay to determine cancer growth.
format Online
Article
Text
id pubmed-7291220
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72912202020-06-17 PPAR Beta/Delta and the Hallmarks of Cancer Wagner, Nicole Wagner, Kay-Dietrich Cells Review Peroxisome proliferator-activated receptors (PPARs) belong to the nuclear hormone receptor family. Three different isoforms, PPAR alpha, PPAR beta/delta and PPAR gamma have been identified. They all form heterodimers with retinoic X receptors to activate or repress downstream target genes dependent on the presence/absence of ligands and coactivators or corepressors. PPARs differ in their tissue expression profile, ligands and specific agonists and antagonists. PPARs attract attention as potential therapeutic targets for a variety of diseases. PPAR alpha and gamma agonists are in clinical use for the treatment of dyslipidemias and diabetes. For both receptors, several clinical trials as potential therapeutic targets for cancer are ongoing. In contrast, PPAR beta/delta has been suggested as a therapeutic target for metabolic syndrome. However, potential risks in the settings of cancer are less clear. A variety of studies have investigated PPAR beta/delta expression or activation/inhibition in different cancer cell models in vitro, but the relevance for cancer growth in vivo is less well documented and controversial. In this review, we summarize critically the knowledge of PPAR beta/delta functions for the different hallmarks of cancer biological capabilities, which interplay to determine cancer growth. MDPI 2020-05-04 /pmc/articles/PMC7291220/ /pubmed/32375405 http://dx.doi.org/10.3390/cells9051133 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Wagner, Nicole
Wagner, Kay-Dietrich
PPAR Beta/Delta and the Hallmarks of Cancer
title PPAR Beta/Delta and the Hallmarks of Cancer
title_full PPAR Beta/Delta and the Hallmarks of Cancer
title_fullStr PPAR Beta/Delta and the Hallmarks of Cancer
title_full_unstemmed PPAR Beta/Delta and the Hallmarks of Cancer
title_short PPAR Beta/Delta and the Hallmarks of Cancer
title_sort ppar beta/delta and the hallmarks of cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291220/
https://www.ncbi.nlm.nih.gov/pubmed/32375405
http://dx.doi.org/10.3390/cells9051133
work_keys_str_mv AT wagnernicole pparbetadeltaandthehallmarksofcancer
AT wagnerkaydietrich pparbetadeltaandthehallmarksofcancer